solver.press

Post-quantum cryptographic techniques for message transformation across network stacks can secure the transmission of sensitive transcriptomic data in Multiple Sclerosis research, ensuring privacy during cross-institutional collaborations.

Computer ScienceApr 13, 2026Evaluation Score: 63%

Adversarial Debate Score

60% survival rate under critique

Model Critiques

mistral: The hypothesis is falsifiable and aligns with the post-quantum cryptography paper, but lacks direct empirical support from the provided excerpts and faces potential counterarguments about practical implementation challenges.
openai: The hypothesis is falsifiable and aligns with the general idea in the "Post-Quantum Cryptographic Analysis" paper that post-quantum cryptography can secure messages across network stacks. However, the support is mostly indirect—none of the papers directly address transcriptomic data or the specif...
anthropic: The hypothesis gains partial support from the existence of directly relevant papers on post-quantum cryptography across network stacks and MS transcriptomics analysis, making the conceptual bridge plausible; however, neither paper explicitly addresses their intersection, the hypothesis lacks empi...
grok: The hypothesis is falsifiable and supported by the paper on post-quantum cryptographic analysis across network stacks, which directly relates to securing data transmission. However, it lacks specific evidence linking these techniques to transcriptomic data privacy in MS research, and potential co...

Supporting Research Papers

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Post-quantum cryptographic (PQC) algorithms—specifically CRYSTALS-Kyber (key encapsulation) and CRYSTALS-Dilithium (digital signatures), as standardized by NIST in 2024—when implemented as a message transformation layer across TCP/IP and application-layer network stacks, will maintain end-to-end confidentiality and integrity of RNA-sequencing transcriptomic datasets (≥10,000 genes, ≥50 patient samples) transmitted between ≥2 geographically distinct MS research institutions, with: (a) encryption overhead <15% of baseline TLS 1.3 throughput, (b) zero plaintext leakage under simulated quantum adversary attacks (Grover/Shor algorithm emulation), and (c) full compliance with HIPAA/GDPR data minimization requirements, compared to classical RSA-2048/ECC-256 baselines under equivalent network conditions.

Disproof criteria:
  1. PERFORMANCE DISPROOF: Measured encryption/decryption throughput overhead exceeds 25% compared to TLS 1.3 baseline on identical hardware for datasets ≥1 GB, making PQC operationally impractical for routine cross-institutional transfers.
  2. SECURITY DISPROOF: Any demonstrated plaintext recovery of ≥1 bit of transcriptomic data under simulated quantum attack (using quantum circuit simulators up to 40 qubits) or classical side-channel attack within the experimental environment.
  3. INTEGRITY DISPROOF: Dilithium signature verification failure rate >0.01% on transmitted datasets, indicating unreliable authentication.
  4. COMPLIANCE DISPROOF: Independent HIPAA/GDPR audit identifies ≥1 category-A violation (e.g., metadata leakage of patient identifiers through packet timing analysis) attributable to the PQC implementation rather than pre-existing infrastructure.
  5. SCALABILITY DISPROOF: System fails to maintain <500 ms key exchange latency when ≥10 simultaneous institutional connections are established (simulating multi-site MS consortium).
  6. INTEROPERABILITY DISPROOF: PQC layer causes >5% packet loss or requires protocol downgrade to classical cryptography in >20% of tested network configurations.
  7. CRYPTOGRAPHIC ASSUMPTION DISPROOF: Publication of a peer-reviewed polynomial-time algorithm solving LWE with security parameter n≥256 would invalidate the foundational assumption regardless of experimental results.

Experimental Protocol

PHASE 1 — Baseline Characterization (Days 1–15): Deploy classical TLS 1.3 (RSA-2048, ECDH-P256) between two emulated institutional nodes. Measure throughput, latency, CPU utilization, and memory consumption for transcriptomic dataset transfers of sizes: 100 MB, 1 GB, 10 GB, 50 GB. Record 30 independent trials per size.

PHASE 2 — PQC Implementation (Days 16–35): Implement CRYSTALS-Kyber-768/1024 + Dilithium3 using Open Quantum Safe (liboqs) library integrated into OpenSSL 3.x fork. Deploy identical network topology. Repeat all Phase 1 measurements under identical conditions.

PHASE 3 — Security Validation (Days 36–50): Conduct adversarial testing: (a) passive eavesdropping with full packet capture, (b) man-in-the-middle with certificate substitution, (c) replay attacks, (d) quantum circuit simulation of Grover's algorithm on 128-bit symmetric keys using Qiskit (up to 30-qubit simulation), (e) timing side-channel analysis using 10,000 repeated handshakes.

PHASE 4 — Compliance Audit (Days 51–60): Independent review of packet metadata, key management logs, and audit trails against HIPAA Security Rule (45 CFR §164.312) and GDPR Article 32 technical measures checklist.

PHASE 5 — Multi-Institutional Simulation (Days 61–75): Emulate 5-node MS research consortium (using GNS3 or AWS VPC peering) with simultaneous transfers. Measure aggregate throughput, key exchange success rate, and error rates.

Required datasets:
  1. MS Transcriptomic Dataset: GTEx MS-relevant tissue RNA-seq data (dbGaP accession phs000424) — 200+ samples, 56,000 genes; or MS4MS consortium synthetic dataset (GDPR-compliant synthetic generation via SDV library if real data access delayed).
  2. Synthetic Patient Metadata: 500 synthetic patient records with realistic MS clinical covariates (EDSS scores, treatment history) generated via Synthea v3.0 for HIPAA compliance testing.
  3. Network Traffic Baseline: CAIDA anonymized packet traces for realistic WAN noise injection.
  4. Quantum Circuit Benchmarks: IBM Quantum Experience open benchmark circuits for Grover's algorithm validation (publicly available).
  5. PQC Reference Implementations: NIST PQC Round 3 submission packages (public domain); liboqs v0.9.0 source code (Apache 2.0).
  6. Cryptographic Test Vectors: NIST ACVTS (Automated Cryptographic Validation Testing System) test vectors for Kyber and Dilithium.
  7. Regulatory Checklist: HHS HIPAA Security Rule audit protocol (public); ENISA GDPR technical guidelines (public).
Success:
  1. Throughput overhead: PQC overhead ≤15% vs TLS 1.3 baseline for all file sizes ≥1 GB (primary criterion, p<0.05, N=30).
  2. Latency: Kyber768 handshake latency ≤200 ms at 99th percentile for single connections; ≤500 ms under 10 simultaneous connections.
  3. Security: Zero plaintext bits recovered in passive eavesdropping test; zero successful MITM attacks; TVLA |t| < 4.5 for timing analysis.
  4. Integrity: Dilithium3 signature verification success rate ≥99.99% across all transferred files.
  5. Quantum resistance: Grover circuit simulation confirms ≥128-bit post-quantum security level (requires >4,000 logical qubits for full attack).
  6. Compliance: ≥95% pass rate on HIPAA Security Rule controls; zero Category-A violations; GDPR Article 32 technical measures fully documented.
  7. Interoperability: <1% packet loss attributable to PQC layer; zero protocol downgrade events in 5-node simulation.
  8. NIST validation: 100% pass rate on ACVTS test vectors for Kyber768 and Dilithium3.
Failure:
  1. Throughput overhead >25% for any dataset size ≥1 GB (hard stop — operationally impractical).
  2. Any plaintext recovery from encrypted transcriptomic data in eavesdropping tests.
  3. Any successful MITM attack that bypasses PQC authentication.
  4. TVLA |t| ≥ 4.5 indicating exploitable timing side-channel.
  5. Dilithium3 verification failure rate >0.01%.
  6. <90% pass rate on HIPAA controls or any Category-A violation.
  7. Key exchange latency >1,000 ms at 99th percentile under single-connection conditions.
  8. 5% packet loss attributable to PQC implementation.

  9. ACVTS test vector failure rate >0% (any cryptographic implementation error is disqualifying).
  10. System crash or memory exhaustion during 50 GB file transfer on specified hardware.

100

GPU hours

30d

Time to result

$1,000

Min cost

$10,000

Full cost

ROI Projection

Commercial:
  1. MARKET SIZE: Global healthcare cybersecurity market projected at $35.3B by 2028 (CAGR 19.1%); PQC-specific healthcare segment estimated at $2.1B by 2030.
  2. PRODUCT OPPORTUNITY: PQC-secured bioinformatics data transfer middleware (SaaS) — addressable market of 2,000+ MS research institutions globally at $50K–$200K/year licensing = $100M–$400M TAM.
  3. STANDARDS INFLUENCE: Validated protocol could become basis for NIH, EMA, or ISO standard for quantum-secure biomedical data sharing, providing first-mover advantage worth $500M+ in government contracts.
  4. INSURANCE VALUE: Cyber insurance premiums for research institutions average $2M–$5M/year; PQC certification could reduce premiums by 15–30% ($300K–$1.5M/year per institution).
  5. PHARMA PARTNERSHIP: MS drug developers (Biogen, Novartis, Roche) spend $500M–$2B/year on real-world evidence data acquisition; secure cross-institutional sharing infrastructure is a critical bottleneck worth $50M–$500M in partnership value.
  6. OPEN SOURCE IMPACT: If released as open-source reference implementation, could be adopted by 500+ biomedical research consortia globally, generating $10M–$50M in indirect economic value through research acceleration.

TIME_TO_RESULT_DAYS: 90

🔓 If proven, this unlocks

Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:

  • 1FEDERATED-LEARNING-PQC-MS-GENOMICS
  • 2PQC-MULTIOMICS-CONSORTIUM-PROTOCOL
  • 3QUANTUM-SECURE-BIOBANK-INFRASTRUCTURE
  • 4PQC-CLINICAL-TRIAL-DATA-SHARING
  • 5CROSS-BORDER-GDPR-PQC-COMPLIANCE-FRAMEWORK
  • 6REAL-TIME-PQC-SCRNA-SEQ-STREAMING

Prerequisites

These must be validated before this hypothesis can be confirmed:

  • PQC-NIST-STD-2024-KYBER
  • LIBOQS-OPENSSL-INTEGRATION-v0.9
  • MS-TRANSCRIPTOMIC-DBGAP-ACCESS
  • HIPAA-AUDIT-FRAMEWORK-v2023
  • SYNTHETIC-PATIENT-DATA-GENERATION

Implementation Sketch

# PQC Transcriptomic Data Transfer System — Architecture Outline

## COMPONENT 1: PQC-TLS Wrapper (Python/C)
class PQCTransferAgent:
    def __init__(self, mode='kyber768_dilithium3'):
        self.kem = liboqs.KeyEncapsulation('Kyber768')
        self.sig = liboqs.Signature('Dilithium3')
        self.hybrid_mode = True  # X25519 + Kyber768 hybrid
    
    def establish_session(self, peer_endpoint):
        # Step 1: Classical X25519 key exchange (backward compat)
        classical_shared = x25519_exchange(peer_endpoint)
        
        # Step 2: Kyber768 KEM encapsulation
        public_key, secret_key = self.kem.generate_keypair()
        ciphertext, kyber_shared = self.kem.encap_secret(peer_public_key)
        
        # Step 3: Hybrid key derivation (HKDF-SHA3-256)
        session_key = HKDF(
            input_key = classical_shared || kyber_shared,
            hash = SHA3_256,
            info = b'MS-transcriptomic-transfer-v1'
        )
        return session_key
    
    def sign_and_send(self, data_chunk, session_key):
        # AES-256-GCM encryption with PQC-derived key
        ciphertext, tag = AES256GCM.encrypt(data_chunk, session_key)
        
        # Dilithium3 signature over ciphertext
        signature = self.sig.sign(ciphertext)
        
        # Packet: [length_header | ciphertext | tag | signature]
        packet = pack_frame(ciphertext, tag, signature)
        return packet
    
    def receive_and_verify(self, packet, session_key):
        ciphertext, tag, signature = unpack_frame(packet)
        
        # Verify Dilithium3 signature BEFORE decryption (fail-fast)
        if not self.sig.verify(ciphertext, signature, peer_public_key):
            raise SecurityException("Signature verification failed")
        
        # Decrypt only after signature verified
        plaintext = AES256GCM.decrypt(ciphertext, tag, session_key)
        return plaintext

## COMPONENT 2: Transcriptomic Data Pipeline Integration
class MSDataTransferPipeline:
    def __init__(self, source_institution, dest_institution):
        self.pqc_agent = PQCTransferAgent()
        self.chunker = AdaptiveChunker(chunk_size_mb=64)  # Optimize for MTU
        self.audit_log = HIPAACompliantLogger()
    
    def transfer_rnaseq_dataset(self, hdf5_file_path, metadata):
        # Strip PII from metadata before transfer
        sanitized_metadata = PIIStripper.process(metadata)
        
        # Establish PQC session
        session = self.pqc_agent.establish_session(dest_institution.endpoint)
        
        # Chunk and transfer
        for chunk in self.chunker.iterate(hdf5_file_path):
            encrypted_packet = self.pqc_agent.sign_and_send(chunk, session.key)
            self.network_send(encrypted_packet)
            self.audit_log.record_transfer_event(
                chunk_hash=SHA3_256(chunk),
                timestamp=UTC_now(),
                institution_pair=anonymized_pair_id
            )
        
        # Transfer completion verification
        self.verify_integrity(session, expected_hash=SHA3_256(full_file))

## COMPONENT 3: Benchmarking Harness
class BenchmarkSuite:
    test_sizes = [100*MB, 1*GB, 10*GB, 50*GB]
    n_trials = 30
    
    def run_comparison(self):
        results = {}
        for size in self.test_sizes:
            results[size] = {
                'tls13_rsa': self.benchmark_classical(size),
                'pqc_kyber768': self.benchmark_pqc(size),
                'overhead_pct': compute_overhead(...)
            }
        return StatisticalReport(results, test='welch_t', alpha=0.05)

## COMPONENT 4: Security Test Suite
class SecurityTestSuite:
    def test_passive_eavesdrop(self): ...  # pcap analysis
    def test_mitm_resistance(self): ...    # mitmproxy integration
    def test_timing_sidechannel(self): ... # TVLA methodology
    def test_quantum_grover(self): ...     # Qiskit circuit simulation
    def test_replay_attack(self): ...      # Nonce/sequence validation

## DEPLOYMENT ARCHITECTURE:
# Institution A ←→ [PQC Gateway A] ←→ [WAN/Internet] ←→ [PQC Gateway B] ←→ Institution B
#                        ↓                                        ↓
#                  [HSM Key Store]                         [HSM Key Store]
#                  [Audit Logger]                          [Audit Logger]
#                        ↓                                        ↓
#                  [SIEM System] ←————— Compliance Dashboard ————→ [SIEM System]
Abort checkpoints:

CHECKPOINT 1 (Day 7): NIST ACVTS test vector validation. ABORT if Kyber768 or Dilithium3 pass rate <100%. Indicates implementation error requiring library replacement or patching before any security claims are valid.

CHECKPOINT 2 (Day 20): Baseline TLS 1.3 benchmarking complete. ABORT if baseline throughput <800 Mbps on 10 GbE hardware (indicates hardware/network misconfiguration that would confound all subsequent comparisons).

CHECKPOINT 3 (Day 35): Initial PQC throughput results. ABORT if overhead >40% for 1 GB files (indicates fundamental performance problem unlikely to be resolved by optimization; hypothesis fails on practicality grounds).

CHECKPOINT 4 (Day 42): Passive eavesdropping test. ABORT IMMEDIATELY if any plaintext transcriptomic data recovered from PQC-encrypted stream (critical security failure; do not proceed to multi-institutional simulation with real data).

CHECKPOINT 5 (Day 50): Timing side-channel analysis. ABORT if TVLA |t| ≥ 4.5 on primary key operations (exploitable side-channel; requires library-level fix before deployment recommendation).

CHECKPOINT 6 (Day 58): HIPAA compliance pre-audit. ABORT if >3 Category-A violations identified (indicates architectural redesign needed; proceeding would produce non-compliant system).

CHECKPOINT 7 (Day 70): Multi-node simulation stability. ABORT if >10% connection failure rate or >15% packet loss in 5-node topology (indicates scalability failure incompatible with real consortium deployment).

CHECKPOINT 8 (Day 80): Integrated system test with synthetic MS data. ABORT if end-to-end transfer of 10 GB synthetic transcriptomic dataset fails to complete within 3× the TLS 1.3 baseline time (combined performance + reliability failure threshold).

📡 New evidence since EVP generation

Discoveries published after this EVP was written that relate to its hypothesis or downstream unlocks.

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started